changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Certain BTG products may not be available within the chosen location and indications may differ from your country's approved use.
For Medical questions regarding any BTG products, please contact firstname.lastname@example.org
A message from Louise Makin, BTG CEO
6 things everyone should know about BTG IM
Our products are used in minimally invasive procedures to treat people with various types of cancer, arteriovenous malformation and to provide palliative intervention targeting diseased cells while decreasing the impact on healthy tissue.
For 10 years, we have been devoted to supporting clinicians in improving the standard of care with innovative medical technologies for millions of emphysema sufferers worldwide.
BTG helps interventional vascular teams solve problems with patients’ blood transport systems through evidence-based innovations that treat smarter and achieve more.
TheraSphere™ yttrium-90 glass microspheres deliver a targeted radiation dose to the tumour whilst minimising exposure to healthy tissue with mild to moderate side effects.15
LC Bead LUMI™ is the first commercially available radiopaque embolic bead for the embolization of hypervascular tumors and arteriovenous malformations in the US.
The unique structure of Bead Block®, PVA hydrogel crosslinked with acrylic polymer, ensures smooth delivery and targeted, effective embolisation, whilst resisting attrition, fragmentation and aggregation.6,7
GALIL™, a leading provider of cryoablation products for the treatment of kidney and other cancers provides clinicians with a broad product portfolio, supported by robust clinical data, to treat a wide range of diseases.
PneumRx™ coils are an implantable shape‐memory device designed to improve lung function in patients with emphysema. CE‐marked, thousands of patients have been treated in Europe since 2008.
EKOS™ is setting the standard for PE treatment safety and efficacy, again. With the EKOS™ treatment’s successful very-low dose and short duration regimens in the OPTALYSE PE trial and favorable long term data results point to a paradigm-changing approach for PE treatment.
TheraSphere® and Radiation Safety Information
Meet the expert:
BTG innovation, Professor Andy Lewis
EKOS Catheter Treatment of Massive & Sub-Massive Pulmonary Emboli
Synergy: A Multidisciplanary Approach to...
Venous Leg Ulcer Registry Shows Promisin...
Trial finds patients receiving CroFab&re...
BTG plc: close period update
OPTALYSE PE Results Presented at Society...
Health Canada approves radiopaque bead f...
Healthcare Player BTG on lookout for acq...